🇺🇸 Ado Trastuzumab Emtansine in United States

2,025 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 2,025

Most-reported reactions

1. Off Label Use — 345 reports (17.04%)
2. Disease Progression — 295 reports (14.57%)
3. Diarrhoea — 289 reports (14.27%)
4. Nausea — 215 reports (10.62%)
5. Fatigue — 189 reports (9.33%)
6. Thrombocytopenia — 153 reports (7.56%)
7. Metastases To Central Nervous System — 146 reports (7.21%)
8. Neuropathy Peripheral — 142 reports (7.01%)
9. Vomiting — 136 reports (6.72%)
10. Neutropenia — 115 reports (5.68%)

Source database →

Frequently asked questions

Is Ado Trastuzumab Emtansine approved in United States?

Ado Trastuzumab Emtansine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ado Trastuzumab Emtansine in United States?

Medstar Health Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.